Versameb raises CHF 6.4 million in Seed C financing round

Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs. RNA therapeutics is a new class of medicines that have broad applicability targeting disease-relevant proteins. Versameb has discovered and developed ways to optimize protein production and targeting through employing modifications in messenger RNA (mRNAs). The VERSagile technology platform enables efficient development of functional mRNA molecules for customized protein expression and modification in various therapeutic indications areas with a high-unmet medical need. This ensures the full exploration of its therapeutic value in different tissues and hence disease areas.

The preclinical biotech company has now obtained fresh capital of CHF 6.4 million in its seed C financing round. The funds will enable the company to expand its proprietary technology platform, VERSagile, in multiple indications and advance the lead program towards clinical studies.

"We are very pleased and grateful to see the interest of new investors, as well as the strong confidence shown by our existing shareholders," said Prof. Dr. Friedrich Metzger, CEO of Versameb.

A new Chairman of Board and Chief Business Officer
Reinhard Ambros joined Versameb as a Member of the Board of Directors and its Chairman succeeding Roger Meier. Reinhard has built the Novartis Venture Fund to a leading corporate biotech venture fund and has held various leadership positions in venture capital, corporate strategy, BD&L and pharmaceutical drug development. His exceptional professional experience adds relevant expertise and insight to Versameb's Board of Directors.

"I was attracted to join Versameb because I see great potential in its unique mRNA technology platform and the ambitious goals to develop next-generation RNA therapies. I look forward to serving as Chairman of the Board and work with this outstanding team to play a part in Versameb's future development", said Reinhard Ambros.

Isabel Ferreira is the new Chief Business Officer. In her role, Isabel Ferreira will be responsible for leading the company's global partnering and corporate development strategy and execution. Isabel Ferreira served most recently in Roche Partnering as Director Global Business Development led strategic projects and cross-functional teams to deal closure. Prior to joining Roche, she acted as Senior Director, Business Development in a Dutch Biotech company that was listed on NASDAQ in a successful IPO in 2013 and was acquired by BioMarin early 2015.

"I am excited to welcome Reinhard and Isabel to our team. Their extensive experience and successful track record deepen our business expertise as we take the company to the next level and execute on our growth strategy," said Friedrich Metzger, CEO of Versameb. "On behalf of the Board, I also thank Roger for his guidance and leadership over the past two years, helping us to successfully grow the company. I am very pleased that he will continue to support us on the Board of Directors."